Inhibrx Biosciences vs Molecular Partners
INBX and MOLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INBX | MOLN |
|---|---|---|
| Size and price | ||
| Market cap | $1.2B | – |
| Share price | $83.30 | $2.94 |
| Change, 1 year | 13.6% | −28.8% |
| Change, 5 years | 92.3% | −71.9% |
| Beta (5Y) | 1.70 | 0.89 |
| Employees | 110 | 34 |
| StockData Score | ||
| Total score | 1 | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| FCF yield | −10.8% | – |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | −36.8% | – |
| Financial health | ||
| Interest coverage | −5.9× (better) | −11.5× |
| Current ratio | 7.58 (better) | 7.27 |
| Altman Z-score | −0.76 | – |
| Piotroski F-score | 1 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 97.4% | 8.9% |
| Held by insiders | 35.4% | 0.00% |
| Insider net buying, 12 months | $6.1M | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 35.7% | – |
Go deeper
- INBX stock overview
- INBX income statement
- INBX valuation and score
- MOLN stock overview
- MOLN income statement
- MOLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.